Literature DB >> 8969316

Canada's new guidelines for the economic evaluation of pharmaceuticals.

D Menon1, F Schubert, G W Torrance.   

Abstract

Mesh：

Year:  1996        PMID： 8969316

Source DB:  PubMed          Journal:  Med Care        ISSN： 0025-7079            Impact factor:   2.983


× No keyword cloud information.
  6 in total

Review 1.  Methodological hurdles in conducting pharmacoeconomic analyses.

Authors:  J D Rizzo; N R Powe
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 2.  Reassessing the relevance of pharmacoeconomic analyses in formulary decisions.

Authors:  J A Johnson; E Friesen
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 3.  Information barriers to the implementation of economic evaluations in Japan.

Authors:  Shuzo Nishimura; George W Torrance; Naoki Ikegami; Shunichi Fukuhara; Michael Drummond; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

Authors:  Peter J Neumann; Chi-Hui Fang; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  A comprehensive qualitative framework for health-related quality of life in Duchenne muscular dystrophy.

Authors:  Philip A Powell; Jill Carlton
Journal:  Qual Life Res       Date:  2022-09-01       Impact factor: 3.440
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.